Skinvisible Continues to Expand its Marketing Efforts to Combat Bird Flu

January 24, 2007

Skinvisible® Continues to Expand its Marketing Efforts to Combat Bird Flu

Skinvisible's Hand Sanitizer Lotion, which kills the Bird Flu virus, H5N1, gets increased exposure to potential Asian distributors

LAS VEGAS, NV., January 24, 2007- Skinvisible Pharmaceuticals, Inc. (OTC Bulletin Board: SKVI), incited by the latest increase in worldwide news reports of a rise in bird flu incidents, has expanded its marketing efforts in Asia, effective immediately. Skinvisible's Chlorhexidine Antimicrobial Hand Sanitizer Lotion with its patented delivery system Invisicare®, can kill the Avian Bird Flu virus, H5N1, with greater than 99.9 percent inactivation - according to studies conducted by Europe's leading contract virology research company Retroscreen Virology (www.skinvisible.com/research). To effectively facilitate our key corporate strategies in targeting the Asian region, Skinvisible has retained Ms. Evelyn Lee as our Regional Corporate Advisor (Hong Kong) to spearhead our activities. Ms. Lee in collaboration with our marketing partner, EMD Chemicals Inc./Merck KGaA, Darmstadt, Germany (Merck KGaA stock symbols Reuters: MRCG, Bloomberg: MRK GY, Frankfurt Stock Exchange: ISIN: DE 000 659 9905 - WKN: 659 990) is introducing Skinvisible's Chlorhexidine Antimicrobial Hand Sanitizer Lotion to potential licensees and various governmental agencies.

"When large reputable publications like the Wall Street Journal cite incident after incident of new cases of the bird flu in Egypt, Japan, China, Indonesia, Vietnam and Hong Kong, you have to take notice." said Terry Howlett, President and CEO of Skinvisible. "We at Skinvisible know that our Chlorhexidine Antimicrobial Hand Sanitizer Lotion, along with regular hand washing, reduces the spread of this H5N1 virus. The active ingredient in Skinvisible's product is Chlorhexidine (klor-HEX-i-deen), an easily tolerated and effective antiseptic that kills or inhibits the growth of disease-causing bacteria, viruses and other microorganisms, and is used for surgical scrubs, skin wounds, germicidal hand rinse and antibacterial dental rinse. This compound is delivered via Skinvisible's patented Invisicare® polymer delivery system. Studies have further shown that our product stays effective for up to four hours and cannot be rubbed off or washed off."

Skinvisible's Chlorhexidine Antimicrobial Hand Sanitizer Lotion has recently received government approval in Canada. Mr. Howlett adds: "We, at Skinvisible, continue our efforts around the globe to expand our reach. This has been an important objective for Skinvisible as its business model is focused on licensing its proprietary formulations with Invisicare® to Pharmaceutical companies worldwide."

About Skinvisible Pharmaceuticals, Inc.

Headquartered in Las Vegas, Nevada, Skinvisible Pharmaceuticals is a research-and-development company that has formulated and patented Invisicare®, an innovative polymer delivery system that enhances the delivery of active ingredients for topically applied skin care products. Skinvisible's primary marketing and sales objective is to license its technology to established brand manufacturers and marketers of Rx and OTC dermatological, medical, cosmetic and skincare products. www.skinvisible.com and www.invisicare.com

Forward-Looking Statements

This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10QSB for the quarter ending June 30, 2006.

BACK TO: News Index

Top